Tapentadol Enhances Canine Anesthesia Stability in Surgery

A New Opioid Option Enhances Anesthesia Stability During Surgery

Managing a dog’s pain during and after surgery is a primary concern for veterinarians and owners. A 2026 study from the University of Messina and University of Parma tested a specific pain medication, tapentadol, given before anesthesia in 66 dogs undergoing spaying. The researchers found this approach improved anesthetic stability and recovery, while also revealing a biological effect on serotonin, a neurotransmitter linked to pain and mood.

Tapentadol Stabilized Vital Signs and Reduced Surgical Stress

Led by Giuseppe Leonardo Costa and colleagues, the team divided dogs into three groups receiving different pre-operative pain protocols. All dogs received a standard propofol-sevoflurane anesthesia. Dogs that received tapentadol, either alone or combined with other pain relief, showed distinct advantages.

Their anesthesia depth was more consistent during the surgical stimulation of ovariectomy. Heart rate and blood pressure—key indicators of surgical stress—were more stable. This suggests the dog’s nervous system was less reactive to the invasive procedure. After surgery, tapentadol-treated dogs were more sedated in the first hour, which resolved by the second hour. This controlled recovery can prevent anxious, disorienting awakenings. Importantly, all groups had adequate pain control post-operatively, and bloodwork remained normal.

The study measured a less expected outcome: plasma serotonin. Dogs receiving tapentadol had significantly lower serotonin levels after surgery compared to controls. Serotonin is involved in complex pain pathways, including descending modulation from the brain. Lower levels might indicate a dampening of pain-related neurochemical activity. This finding opens a window into how this particular opioid, which works on both opioid receptors and norepinephrine reuptake, might achieve its effects beyond simple receptor blocking.

Laser Therapy Shows Potential for Reducing NSAID Dependence

For chronic conditions like osteoarthritis, long-term pain management is needed. A separate knowledge summary by Ciar Fitzpatrick reviewed evidence for laser therapy in dogs with OA. The PICO-question analysis found one randomized controlled trial suggesting that adding laser treatment to a non-steroidal anti-inflammatory drug regimen improved clinical pain scores.

In that trial, dogs receiving concurrent laser therapy saw their Helsinki chronic pain scores improve, their lameness scores improve, and their required NSAID dose reduced. The control group receiving only NSAIDs did not show improved lameness. Fitzpatrick notes the strength of this evidence is currently weak, based on a single study, and more research is needed. However, the potential is significant. Reducing reliance on NSAIDs, which can have side effects on the kidneys, liver, and gastrointestinal tract over time, is a valuable goal. Laser therapy, a non-invasive and drug-free modality, may offer a way to achieve that.

Integrating New Evidence into Veterinary Pain Management Plans

These studies highlight two different but complementary aspects of veterinary analgesia: acute surgical pain and chronic degenerative pain. The tapentadol research provides a specific, evidence-backed option for improving the perioperative experience. Giving an analgesic before induction, known as preemptive analgesia, can block pain pathways before they are activated, often leading to better outcomes. Tapentadol’s dual mechanism may offer advantages over older opioids, though it requires veterinary-specific dosing and monitoring.

For the aging dog with stiff joints, the laser therapy summary suggests a multi-modal approach can be more effective than a single drug. Combining a pharmaceutical (NSAID) with a physical modality (laser) targets pain through different mechanisms—reducing inflammation and stimulating cellular repair and circulation. This aligns with the broader veterinary principle of multi-modal pain management, which seeks to improve efficacy and reduce side effects by using several low-dose methods instead of one high-dose drug. Owners should discuss such combinations with their veterinarian, as each dog’s health profile influences the safest plan.

A limitation of the osteoarthritis review is the acknowledged weak evidence; it points to a need for more high-quality trials. The tapentadol study was robust but focused on a single, elective surgery in healthy dogs. Its findings may not translate directly to more complex surgeries or dogs with illnesses. However, both pieces of research contribute to a growing toolkit. As with other areas of pet health, such as urinary tract health or kidney disease management, personalized, evidence-informed plans are the goal.

Conclusion

Modern dog pain management is moving beyond generic prescriptions. Specific pre-operative medications like tapentadol can stabilize anesthesia and improve recovery from surgery. For chronic osteoarthritis, combining treatments like laser therapy with NSAIDs may improve comfort while reducing drug exposure. Ongoing research continues to refine these options, giving veterinarians more strategies to ensure canine comfort and welfare.

Sources:
https://pubmed.ncbi.nlm.nih.gov/42076750/
https://pubmed.ncbi.nlm.nih.gov/42006385/